DM Bio

DM Bio is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and manufacturing of mammalian cell culture-based therapeutic proteins and monoclonal antibodies. Established as a joint venture between Dong A Socio Holdings and Meiji Seika Pharma, both of which possess extensive histories in the pharmaceutical industry of Korea and Japan, DM Bio began its manufacturing operations in 2015. The company is dedicated to meeting the specific demands of global biotechnology companies, leveraging highly qualified experts and state-of-the-art manufacturing facilities.

Services include:
- Development of mammalian cell culture-based therapeutic proteins
- Manufacture of monoclonal antibodies
- Process development and optimization
- Quality control and assurance
- Regulatory support
- Product characterisation and testing

DM Bio is committed to providing high-quality services tailored to the needs of the pharmaceutical industry. For more information, please visit dmbio.com.